{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:12:24Z","timestamp":1791180744419,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3499,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,2]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Early treatment of acute hepatitis C with interferon alpha-2b for 24 weeks prevents chronic infection in almost all patients. Because pegylated interferons have replaced conventional interferon in the therapy of chronic hepatitis C, the aim of this study was to analyze the efficacy of an early treatment of acute hepatitis C with peginterferon alfa- 2b. Between February 2001 and February 2004, 89 individuals with acute HCV infection were recruited at 53 different centers in Germany. Patients received 1.5 \u03bcg\/kg peginterferon alfa-2b for 24 weeks; treatment was initiated after a median of 76 days after infection (range 14-150). End-of-treatment response and sustained virological response were defined as undetectable HCV RNA at the end of therapy and after 24 weeks of follow-up, respectively. In the total study population, virological response was 82% at the end of treatment and 71% at the end of follow-up. Of 89 individuals, 65 (73%) were adherent to therapy, receiving 80% of the interferon dosage within 80% of the scheduled treatment duration. End-of-treatment and sustained virological response rates in this subpopulation were 94% and 89%, respectively. A maximum alanine aminotransferase level of more than 500 U\/L prior to therapy was the only factor associated with successful treatment.<\/jats:bold>\n                                 <jats:bold>\n                                    In conclusion\n                                 <\/jats:bold>\n                                 <jats:bold>, in acute HCV infection, early treatment with peginterferon \u03b12b leads to high virological response rates in individuals who are adherent to treatment. The high number of dropouts underlines the importance of thorough patient selection and close monitoring during therapy. Thus, future studies should identify factors predicting spontaneous viral clearance to avoid unnecessary therapy. (Hepatology 2006;43:250\u2013256.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.21043","type":"journal-article","created":{"date-parts":[[2006,1,27]],"date-time":"2006-01-27T02:46:26Z","timestamp":1138329986000},"page":"250-256","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":188,"title":["Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study"],"prefix":"10.1097","volume":"43","author":[{"given":"Johannes","family":"Wiegand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Buggisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulf","family":"Boecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia M.","family":"Gelbmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Kauffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Kallinowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Jaeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20241201","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/hep.20221","article-title":"Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C.","volume":"39","author":"Wedemeyer","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R2-7-20241201","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2004.12.012","article-title":"Treatment of acute hepatitis C infection: more pieces of the puzzle?","volume":"42","author":"Zekry","year":"2005","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"R3-7-20241201","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C.","volume":"36","author":"Seeff","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R4-7-20241201","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa2b plus ribavirin compared with interferon alfa2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R5-7-20241201","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R6-7-20241201","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"R7-7-20241201","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJM199212313272702","article-title":"The natural history of communityacquired hepatitis C in the United States. The Sentinel Counties Chronic nonA, nonB Hepatitis Study Team.","volume":"327","author":"Alter","year":"1992","journal-title":"N Engl J Med"},{"key":"R8-7-20241201","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1017\/S0950268802007902","article-title":"Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature.","volume":"129","author":"Roy","year":"2002","journal-title":"Epidemiol Infect"},{"key":"R9-7-20241201","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/jhep.2001.22112","article-title":"Acute hepatitis C.","volume":"33","author":"Orland","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R10-7-20241201","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11901-004-0025-6","article-title":"Acute hepatitis C infection: can immunology teach us the right way to treat?","volume":"3","author":"Wiegand","year":"2004","journal-title":"Curr Hepat Rep"},{"key":"R11-7-20241201","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa2b.","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"R12-7-20241201","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C: high rate of both spontaneous and treatmentinduced viral clearance.","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"R13-7-20241201","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.20196","article-title":"Shortterm interferonalfa therapy for acute hepatitis C: a randomized controlled trial.","volume":"39","author":"Nomura","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R14-7-20241201","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/hep.20266","article-title":"Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virusspecific T cell response kinetics.","volume":"39","author":"Kamal","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R15-7-20241201","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2036.2004.02023.x","article-title":"Treatment of acute hepatitis C with interferon alpha2b: early initiation of treatment is the most effective predictive factor of sustained viral response.","volume":"20","author":"Delwaide","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-7-20241201","doi-asserted-by":"crossref","first-page":"W91","DOI":"10.7326\/0003-4819-141-6-200409210-00031-w1","article-title":"Waitandsee: an alternative approach to managing acute hepatitis C with highdose interferonalpha monotherapy.","volume":"141","author":"Pimstone","year":"2004","journal-title":"Ann Intern Med"},{"key":"R17-7-20241201","first-page":"294","article-title":"Early treatment of acute hepatitis C with interferon alpha2b or interferon alpha2b plus ribavirin: study of sixteen patients.","volume":"27","author":"Rocca","year":"2003","journal-title":"Gastroenterol Clin Biol"},{"key":"R18-7-20241201","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jhep.2004.11.018","article-title":"Barriers to interferonalpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C.","volume":"42","author":"Broers","year":"2005","journal-title":"J Hepatol"},{"key":"R19-7-20241201","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2004.11.021","article-title":"Efficacy of a 24week course of PEGinterferon alpha2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.","volume":"42","author":"Santantonio","year":"2005","journal-title":"J Hepatol"},{"key":"R20-7-20241201","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/hep.510380302","article-title":"The German Network of Excellence for Viral Hepatitis (HEPNET).","volume":"38","author":"Manns","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R21-7-20241201","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized, doubleblind trial comparing pegylated interferon alfa2b to interferon alfa2b as initial treatment for chronic hepatitis C.","volume":"34","author":"Lindsay","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R22-7-20241201","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.20291","article-title":"Longterm followup after successful interferon therapy of acute hepatitis C.","volume":"40","author":"Wiegand","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R23-7-20241201","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1136\/gut.50.5.693","article-title":"Infection rate and spontaneous seroreversion of antihepatitis C virus during the natural course of hepatitis C virus infection in the general population.","volume":"50","author":"Kondili","year":"2002","journal-title":"Gut"},{"key":"R24-7-20241201","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/jhep.2003.50019","article-title":"Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load.","volume":"37","author":"Hofer","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R25-7-20241201","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0168-8278(03)00461-6","article-title":"When and how to treat acute hepatitis C?","volume":"39","author":"Licata","year":"2003","journal-title":"J Hepatol"},{"key":"R26-7-20241201","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jmv.20103","article-title":"High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.","volume":"73","author":"Lehmann","year":"2004","journal-title":"J Med Virol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21043","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200602000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:02:39Z","timestamp":1733054559000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200602000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21043","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}